Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia

References

• Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. American Journal of Psychiatr 1993; 150: 1405–1407
   PubMed Web of Science ®Google Scholar
• Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry 1999; 56: 836–841
   PubMed Web of Science ®Google Scholar
• Allen RG, Balin AK. Oxidative influence on development and differentiation: An overview of a free radical theory of development. Free Radical Biology & Medicine 1989; 6: 631–661
   PubMed Web of Science ®Google Scholar
• Anderson GJ, Connor WE, Corliss JD. Docosahexaenoic acid is the preferred dietary n-3 fatty acid for the development of the brain and retina. Pediatric Research 1990; 27: 89–97
   PubMed Web of Science ®Google Scholar
• Arnold SE, Trojanowski JQ, Gur RE, Blackwell P, Han L-Y, Choi C. Absence of neurodegenerative and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Archives of General Psychiatry 1998; 55: 225–232
   PubMedGoogle Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003a; 62: 195–204
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biological Psychiatry 2003b; 53: 56–64
   PubMed Web of Science ®Google Scholar
• Behl C, Rupprecht R, Skutella T, Holsboer F. Haloperidol-induced cell death—mechanism and protection with vitamin E in vitro. NeuroReport 1995; 7: 360–364
   PubMed Web of Science ®Google Scholar
• Bender L. Childhood schizophrenia: Clinical study of 100 schizophrenic children. American Journal of Psychiatry 1947; 17: 40–56
   Google Scholar
• Bernstein HG, Krell D, Braunewell KH, Baumann B, Gundelfinger ED, Diekmann S, et al. Increased number of nitric oxide synthase immunoreactive Purkinje cells and dentate nucleus neurons in schizophrenia. Journal of Neurocytology 2001; 30: 661–670
   PubMedGoogle Scholar
• Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29: 697–701
   PubMed Web of Science ®Google Scholar
• Burgess JR, Kuo C-F. Increased calcium-dependent phospholipase A2 activity in vitamin E, and selenium-deficient rat lung, liver and spleen cytosol is time-dependent and reversible. The Journal of Nutritional Biochemistry 1996; 7: 366–374
   Web of Science ®Google Scholar
• Cadet JL, Lohr JB. Free radicals and the developmental pathophysiology of schizophrenic burnout. Integrative Psychiatry 1987; 5: 40–48
   Google Scholar
• Cadet JL, Perumal AS. Chronic treatment with prolixine causes oxidative stress in rat brain. Biological Psychiatry 1990; 28: 738–740
   PubMed Web of Science ®Google Scholar
• Cannon M, Jones P, Gilvarry C, Rifkin L, Mckenzie K, Foerster A, et al. Premorbid social functioning in schizophrenia and bipolar disorder: Similarities and differences. American Journal of Psychiatry 1997; 154: 1544–1550
   PubMed Web of Science ®Google Scholar
• Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: Historical and meta-analytic review. American Journal of Psychiatry 2002; 159: 1080–1092
   PubMed Web of Science ®Google Scholar
• Catts VS, Catts SV. Apoptosis and schizophrenia: Is the tumor suppressor gene, p53, a candidate susceptibility gene?. Schizophrenia Research 2000; 41: 405–415
   PubMed Web of Science ®Google Scholar
• Christinsen O, Christinsen E. Fat consumption and schizophrenia. Acta Psychiatrica Scandinavica 1988; 78: 587–591
   PubMedGoogle Scholar
• Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. The Journal of Biological Chemistry 2002; 277: 3101–3108
   PubMed Web of Science ®Google Scholar
• Collins AR, Dusinska M, Gedik CM, Stetina R. Oxidative damage to DNA: Do we have a reliable biomarker?. Environmental Health Perspectives 1996; 104: 465–469
   PubMed Web of Science ®Google Scholar
• Connor WE, Lin DS, Neuringer M. The Docosahexaenoic Acid (Dha. 22:6n-3) contents of erythrocytes a marker for the DHA content of brain phospholipids?. The FASEB Journal 1993; 7: A152
   Web of Science ®Google Scholar
• Craig TJ, Siegel C, Hopper K, Lin S, Sartorius N. Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. The British Journal of Psychiatry 1997; 170: 229–233
   PubMed Web of Science ®Google Scholar
• Cui K, Luo X, Xu K, Ven Murthy MR. Role of oxidative stress in neurodegeneration: Recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Progress in Neuropsychopharmacology & Biological Psychiatry 2004; 28: 771–799
   PubMed Web of Science ®Google Scholar
• Das UN. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent schizophrenia in adult life?. Medical Science Monitor 2004; 10: HY33–HY37
   PubMedGoogle Scholar
• Dawson TM, Dawson VL, Snyder SH. A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Annals of Neurology 1992; 32: 297–311
   PubMed Web of Science ®Google Scholar
• Degreef G, Ashtari M, Bogerts B, Bilder R, Jody DN, Alvir JMJ, et al. Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. Archives of General Psychiatry 1992; 49: 531–537
   PubMed Web of Science ®Google Scholar
• DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Research 1997; 74: 129–140
   PubMed Web of Science ®Google Scholar
• DeLisi LE, Hoff A, Kushner M, Calev A, Stritzke P. Ventricular enlargement at the onset of psychosis is associated with diagnostic outcome. Biological Psychiatry 1992; 32: 199–201
   PubMedGoogle Scholar
• Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2003; 69: 393–399
   PubMed Web of Science ®Google Scholar
• Fammy C, Streissguth AP, Unis AS. Mental illness in adults with fetal alcohol syndrome or fetal alcohol effects. American Journal of Psychiatry 1998; 155: 552–554
   PubMedGoogle Scholar
• Faraci FM, Brian JE, Jr. Nitric oxide and the cerebral circulation. Stroke 1994; 25: 692–703
   PubMed Web of Science ®Google Scholar
• Fenton WS, Hibbelin J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 2000; 47: 8–21
   PubMed Web of Science ®Google Scholar
• Fish B, Marcus J, Hans S, Auerbach JG, Perdue S. Infants at risk for schizophrenia: Sequelae of a genetic neuro-integrative defect. Archives of General Psychiatry 1992; 49: 221–235
   PubMed Web of Science ®Google Scholar
• Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proceedings of the National Academy of Sciences of the United States of America 1989; 86: 6377–6381
   PubMed Web of Science ®Google Scholar
• Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry 1998; 65: 446–453
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Hubner CK, Nevalainen TJ, Thuren T, Kinnunen PKJ. Increased serum phospholipase A2 activity in schizophrenia: A replication study. Biological Psychiatry 1990; 28: 495–501
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Schmitt A, Athanasios M. Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research 1995; 16: 1–6
   PubMed Web of Science ®Google Scholar
• Gerding LB, Labbate LA, Meason MO, Santos AB, Arano GW. Alcohol dependence and hospitalization in schizophrenia. Schizophrenia Research 1999; 38: 71–75
   PubMed Web of Science ®Google Scholar
• Glen AIM, Glen EMT, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: Evidence for two diseases. Schizophrenia Research 1994; 12: 53–61
   PubMed Web of Science ®Google Scholar
• Gupta S, Andreasen NC, Arndt S, Flaum M, Schultz SK, Hubbard WC, et al. Neurological soft signs in neuroleptic-naive and neuroleptic treated schizophrenic patients and normal comparison subjects. American Journal of Psychiatry 1995; 152: 191–196
   PubMed Web of Science ®Google Scholar
• Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, et al. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry 1998; 55: 145–152
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. Antioxidants of human extracellular fluids. Archives of Biochemistry and Biophysics 1990; 280: 1–8
   PubMed Web of Science ®Google Scholar
• Halliwell B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs & Aging 2001; 18: 685–716
   PubMed Web of Science ®Google Scholar
• Hanson DR, Gottesman II. Theories of schizophrenia: A genetic-inflammatory-vascular synthesis. BMC Medical Genetics 2005; 11: 6–7
   Google Scholar
• Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Molecular Psychiatry 2005; 10: 40–68
   PubMed Web of Science ®Google Scholar
• Heckers S. Neuropathology of schizophrenia: Cortex, thalamus, basal ganglia, and neurotransmitter-specific projection system. Schizophrenia Bulletin 1997; 23: 403–421
   PubMedGoogle Scholar
• Herken H, Uz E, Ozyurt H, Akyol O. Red blood cell nitric oxide levels in patients with schizophrenia. Schizophrenia Research 2001a; 52: 289–290
   PubMed Web of Science ®Google Scholar
• Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular Psychiatry 2001b; 6: 66–73
   PubMed Web of Science ®Google Scholar
• Ho L, Pasinetti GM, Horrocks LA, Farooqui AA, Horrobin DF, Peet M, et al. Eicosanoid pathways and psychiatric disorders. Biological Psychiatry 2000; 47: 114S
   Google Scholar
• Hoffer A, Osmond H, Smythies J. Schizophrenia; a new approach. II. Result of a year's research. The Journal of Mental Science 1954; 100: 29–45
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Is the main problem in free radical damage caused by radiation, oxygen, and other toxins the loss of membrane essential fatty acids rather than the accumulation of toxic materials?. Medical Hypotheses 1991; 35: 23–36
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1996; 55: 3–8
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Manku MS, Hillman S, Glen IAM. Fatty acid levels in brains of schizophrenics and normal controls. Biological Psychiatry 1991; 30: 795–805
   PubMed Web of Science ®Google Scholar
• Horrocks LA, Farooqui AA. Docosahexaenoic acid in the diet: Its importance in maintenance and restoration of neural membrane function. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004; 70: 361–372
   PubMed Web of Science ®Google Scholar
• Hungund BL, Mahadik SP. Role of gangliosides in behavioral and biochemical actions of alcohol: Cell membrane structure and function. Alcoholism, Clinical and Experimental Research 1993; 17: 329–339
   PubMedGoogle Scholar
• Ikemoto A, Nitta A, Furukawa S, Ohishi M, Nakamura A, Fujii Y, et al. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neuroscience Letters 2000; 285: 99–102
   PubMed Web of Science ®Google Scholar
• Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization 10-country study. Psychological Medicine. Monograph Supplement 1992; 20: 1–97
   PubMedGoogle Scholar
• Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2005; 29: 846–858
   PubMed Web of Science ®Google Scholar
• Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochemical Pharmacology 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Karson CN, Griffin WS, Mrak RE, Husain M, Dawson TM, Snyder SH, et al. Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis. Molecular and Chemical Neuropathology 1996; 27: 275–284
   PubMedGoogle Scholar
• Katila H, Appleberg B, Rimon R. No differences in phospholipase-A2 activity between acute psychiatric patients and controls. Schizophrenia Research 1997; 26: 103–105
   PubMedGoogle Scholar
• Keller A, Castellanos FX, Vaituzis AC, Jeffries NO, Giedd JN, Rapoport JL. Progressive loss of cerebellar volume in childhood-onset schizophrenia. American Journal of Psychiatry 2003; 160: 128–133
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Anderson S, Pettegrew JW. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg Hypothesis revisited. Journal of Psychiatric Research 1994; 28: 239–265
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Research 1993; 49: 89–95
   PubMed Web of Science ®Google Scholar
• Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with anti-psychotics. Schizophrenia Research 2002; 58: 1–10
   PubMed Web of Science ®Google Scholar
• Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, et al. Oxidative stress during treatment with first- and second- generation anti-psychotics. The Journal of Neuropsychiatry and Clinical Neuroscience 2005; 17: 227–231
   PubMed Web of Science ®Google Scholar
• Lane A, Kinsella A, Murphy P, Byrne M, Keenan J, Colgan K, et al. The anthropometric assessment of dysmorphic features in schizophrenia as an index of its developmental origins. Psychological Medicine 1997; 27: 1155–1172
   PubMed Web of Science ®Google Scholar
• Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia: A systematic and quantitative review of volumetric magnetic resonance imaging studies. The British Journal of Psychiatry 1998; 172: 119–120
   Google Scholar
• Lawrie SM, Whalley H, Kestelman JN, Abukmeil SS, Byrne M, Hodges A, et al. Magnetic resonance imaging of brain in people at high risk of developing schizophrenia. Lancet 1999; 353: 30–33
   PubMed Web of Science ®Google Scholar
• Leon JD. Smoking and vulnerability for schizophrenia. Schizophrenia Bulletin 1996; 22: 405–409
   PubMedGoogle Scholar
• Li XM, Chan-Forney J, Julio AV, Bennett VL, Shrikhande S, Keegan DL, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. Journal of Neuroscience Research 1999; 56: 72–75
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biological Psychiatry 1999; 46: 729–739
   PubMed Web of Science ®Google Scholar
• Lieberman J, Bogerts B, Degreef G, Ashtari AJ. Qualitative assessment of brain morphology in acute and chronic schizophrenia. American Journal of Psychiatry 1992; 149: 784–794
   PubMed Web of Science ®Google Scholar
• Lohr JB, Underhill S, Moir S, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biological Psychiatry 1990; 28: 535–539
   PubMed Web of Science ®Google Scholar
• Loven DP, James JF, Biggs L, Little KY. Increased manganese-superoxide dismutase superoxide dismutase activity in postmortem brain from neuroleptic-treated psychotic patients. Biological Psychiatry 1996; 40: 230–232
   PubMedGoogle Scholar
• Mahadik SP, Evans D. Essential fatty acids in the treatment of schizophrenia. Drugs of Today 1997; 33: 5–17
   Google Scholar
• Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 2001; 25: 463–493
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Gowda S. Antioxidants in the treatment of schizophrenia. Drugs of Today 1996; 32: 1–13
   Google Scholar
• Mahadik SP, Mukherjee S. Free radical pathology and the antioxidant defense in schizophrenia. Schizophrenia Research 1996; 19: 1–18
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1996; 55: 45–54
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Mukherjee S, Correnti EE, Scheffer R, Mahadik J. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biological Psychiatry 1998; 43: 674–679
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Mulchandani M, Hegde MV, Ranjekar PK. Cultural and socioeconomic differences in dietary intake of essential fatty acids and antioxidants: Effects on the outcome. Phospholipid Spectrum Psychiatric Disorders, D Horrobin, AL Glen, M. Peet. Marius Press, Carnforth, UK 1999a; 167
   Google Scholar
• Mahadik SP, Sitasawad V, Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. Phospholipid Spectrum Psychiatric Disorders, D Horrobin, AL Glen, M. Peet. Marius Press, Carnforth, UK 1999b; 99
   Google Scholar
• Margolis RL, Chung D-M, Post RM. Programmed cell death: Implications for neuropsychiatric disorders. Biological Psychiatry 1994; 35: 946–956
   PubMed Web of Science ®Google Scholar
• Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: A longitudinal magnetic resonance imaging study. Archives of General Psychiatry 2001; 58: 148–157
   PubMed Web of Science ®Google Scholar
• McCreadie RG, MacDonald E, Wiles D, Campbell G, Paterson JR. The Nithsdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patients with and without tardive dyskinesia, and in normal subjects. The British Journal of Psychiatry 1995; 167: 610–617
   PubMed Web of Science ®Google Scholar
• McDonald C, Murray RM. Early and late environmental risk factors for schizophrenia. Brain Research. Brain Research Reviews 2000; 31: 130–137
   PubMed Web of Science ®Google Scholar
• Mellor JE, Laugharne JDE, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophrenia Research 1995; 18: 85–86
   PubMedGoogle Scholar
• Michel TM, Thome J, Martin D, Nara K, Zwerina S, Tatschner T, et al. Cu, Zn- and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. Journal of Neural Transmission 2004; 111: 1191–1201
   PubMed Web of Science ®Google Scholar
• Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 1994; 263: 973–977
   PubMed Web of Science ®Google Scholar
• Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SN, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: Smoking as a cause of oxidative damage. The New England Journal of Medicine 1995; 332: 1198–1203
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research 1996; 19: 19–26
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mahadik SP, Horrobin DF, Jenkins K, Correnti E, Scheffer R. Membrane fatty acid composition of fibroblasts from schizophrenic patients. Biological Psychiatry 1994; 35: 700
   Google Scholar
• Muller DPR. Neurological disease. Antioxidants in Disease Mechanisms and Therapy , H Sies. Academic Press, New York 1997; 557
   Google Scholar
• Niznikiewicz M, Kubicki M, Shenton M. Recent structural and functional imaging findings in schizophrenia. Current Opinion in Psychiatry 2003; 16: 123–147
   Web of Science ®Google Scholar
• Noh JS, Kang HJ, Kim EY, Sohn S, Chung YK, Kim SU, et al. Haloperidol-induced neuronal apoptosis: Role of p38 and c-Jun-NH(2)-terminal protein kinase. Journal of Neurochemistry 2000; 75: 2327–2334
   PubMed Web of Science ®Google Scholar
• Noponen M, Sanfilipo M, Samanich K, Ryer H, Angrist B, Wolkin A, et al. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biological Psychiatry 1993; 34: 641–649
   PubMed Web of Science ®Google Scholar
• Olanow CW. A radical hypothesis for neurodegeneration. Trends in Neurosciences 1993; 16: 439–444
   PubMed Web of Science ®Google Scholar
• Pall HS, Williams AC, Blake DR, Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987; 2: 596–599
   PubMed Web of Science ®Google Scholar
• Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: Possible implications for treatment outcome. Schizophrenia Research 2003b; 60: 117–123
   PubMed Web of Science ®Google Scholar
• Parikh V, Khan MM, Mahadik SP. Differential effects of anti-psychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. Journal of Psychiatric Research 2003a; 37: 43–51
   PubMed Web of Science ®Google Scholar
• Peet M, Horrobin DF, the E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. Journal of Psychiatric Research 2002; 36: 7–18
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. International Clinical Psychopharmacology 1993; 8: 151–153
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1996; 55: 71–75
   PubMed Web of Science ®Google Scholar
• Peet M, Stokes C. Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs 2005; 65: 1051–1059
   PubMed Web of Science ®Google Scholar
• Peet M, Mellor J. Double blind placebo controlled trial of n-3 polyunsaturated fatty acids as an adjunct to neuroleptics. Ninth Schizophrenia Winter Workshop 1998; 54
   Google Scholar
• Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, et al. Predictors of anti-psychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. The British Journal of Psychiatry 2004; 185: 18–24
   PubMed Web of Science ®Google Scholar
• Pillai A, Parikh V, Terry Jr AV, Mahadik SP. Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and lipid peroxidation in adult rat brain. Journal of Psychiatric Research, In press
   Google Scholar
• Pitsikas N, Algeri S. Deterioration of spatial and nonsocial reference working memory in aged rats: Protective effect of life-long caloric restriction. Neurobiology of Aging 1992; 13: 369–373
   PubMed Web of Science ®Google Scholar
• Pryor WA, Stone K. Oxidants in cigarette smoke: Radicals hydrogen peroxide, peroxinitrate, and peroxinitrate. Annals of the New York Academy of Sciences 1993; 1012: 12–28
   Google Scholar
• Psimadas D, Messini-Nikolaki N, Zafiropoulou M, Fortos A, Tsilimigaki S, Piperakis SM. DNA damage and repair efficiency in lymphocytes from schizophrenic patients. Cancer Letters 2004; 204: 33–40
   PubMed Web of Science ®Google Scholar
• Rafalowska U, Liu G-J, Floyd RA. Peroxidation induced changes in synaptosomal transport of dopamine and γ-aminobutyric acid. Free Radical Biology & Medicine 1989; 6: 485–492
   PubMed Web of Science ®Google Scholar
• Ramirez J, Garnica R, Boll MC, Montes S, Rios C. Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: A pilot study. Schizophrenia Research 2004; 68: 357–361
   PubMed Web of Science ®Google Scholar
• Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003; 121: 109–122
   PubMed Web of Science ®Google Scholar
• Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophrenia Research 2003; 62: 205–212
   PubMed Web of Science ®Google Scholar
• Reddy R, Yao J. Free radical pathology in schizophrenia: A review. Prostaglandins, Leukotrienes, and Essential Fatty Acids 1996; 55: 33–43
   PubMed Web of Science ®Google Scholar
• Reddy R, Mahadik SP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biological Psychiatry 1991; 30: 309–312
   Google Scholar
• Reiter RJ. Oxidative processes and anti-oxidative defense mechanisms in the aging brain. The FASEB Journal 1995; 9: 526–533
   PubMed Web of Science ®Google Scholar
• Rice-Evans CA, Diplock AT. Current status of antioxidant therapy. Free Radical Biology & Medicine 1993; 15: 77–96
   PubMed Web of Science ®Google Scholar
• Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia: Evidence for the involvement of a calcium-dependent phospholipase A2. Archives of General Psychiatry 1997; 54: 487–494
   PubMed Web of Science ®Google Scholar
• Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. Psychopharmacology: The Third Generation of Progress, HY Meltzer. Raven Press, New York 1987; 759
   Google Scholar
• Roy D, Pathak DN, Singh R. Effects of chlorpromazine on the activities of antioxidant enzymes and lipid peroxidation in the various regions of aging rat brain. Journal of Neurochemistry 1984; 42: 628–633
   PubMed Web of Science ®Google Scholar
• Scheffer RD, Bradley J, Mahadik SP. Elevated lipid peroxidation and phospholipase A2: Possible mechanism of the lower cell membrane essential polyunsaturated fatty acids in schizophrenia. Biological Psychiatry 1999; 43: 101
   Google Scholar
• Schwartz RD, Skolnick P, Paul SM. Regulation of gamma-aminobutyric acid/barbiturate receptor gated chloride ion flux in brain vesicles by phospholipase A2: Possible role of oxygen radicals. Journal of Neurochemistry 1988; 50: 565–571
   PubMedGoogle Scholar
• Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex. Archives of General Psychiatry 1995; 52: 805–818
   PubMed Web of Science ®Google Scholar
• Senitz D, Winkelmann E. Neuronal structure abnormality in the orbito-frontal cortex of schizophrenics. Journal fur Hirnforschung 1991; 32: 149–158
   PubMedGoogle Scholar
• Shah S, Vankar GK, Telang SD, Ramchand CN, Peet M. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. Schizophrenia Research 1998; 29: 158
   Google Scholar
• Shriqui CL, Bradjewejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: A double-blind placebo-controlled study. American Journal of Psychiatry 1992; 149: 391–393
   PubMed Web of Science ®Google Scholar
• Simopoulos AP. Omega-3 fatty acids in health and disease, and in growth and development. The American Journal of Clinical Nutrition 1991; 54: 438–463
   PubMed Web of Science ®Google Scholar
• Smalheiser NR, Swanson DR. Calcium-dependent phospholipase A2 and schizophrenia. Letter to the Editor. Archives of General Psychiatry 1998; 55: 752–753
   PubMedGoogle Scholar
• Sohal RS, Ku H-H, Agarwal S, Forster MJ, Lal H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging, and in response to food restriction in the mouse. Mechanisms of Ageing and Development 1994; 74: 121–133
   PubMed Web of Science ®Google Scholar
• Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: A preliminary study. Schizophrenia Bulletin 2003; 29: 393–397
   PubMed Web of Science ®Google Scholar
• Suboticanec K, Folnegovic V, Korbar M, Mestrovic B, Buzina R. Vitamin C status in chronic schizophrenia. Biological Psychiatry 1990; 28: 959–966
   PubMed Web of Science ®Google Scholar
• Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. The New England Journal of Medicine 1990; 322: 789–794
   PubMed Web of Science ®Google Scholar
• Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Archives of Medical Research 2004; 35: 401–405
   PubMed Web of Science ®Google Scholar
• Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutaminergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry 1998; 155: 1207–1213
   PubMed Web of Science ®Google Scholar
• Urakubo A, Jarskog LF, Lieberman JA, Gilmore JH. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophrenia Research 2001; 47: 27–36
   PubMed Web of Science ®Google Scholar
• Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acids supplementation in patients with tardive dyskinesia. Psychiatry Research 1989; 27: 313–323
   PubMed Web of Science ®Google Scholar
• Van Den Berg JJM, Op Den Kamp JAF, Lubin BH, Kuypers FA. Conformational changes in oxidized phospholipids and their preferential hydrolysis by phospholipase A2: A monolayer study. Biochemistry 1993; 32: 4962–4967
   PubMedGoogle Scholar
• Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Archives of General Psychiatry 1987; 44: 660–669
   PubMed Web of Science ®Google Scholar
• Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Archives of General Psychiatry 1986; 43: 114–124
   PubMed Web of Science ®Google Scholar
• Wood KA, Youle RJ. Apoptosis and free radicals. Annals of the New York Academy of Sciences 1994; 738: 400–407
   PubMed Web of Science ®Google Scholar
• Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. Journal of Neurotrauma 2004; 21: 1457–1467
   PubMed Web of Science ®Google Scholar
• Wyatt RJ. Early intervention of schizophrenia: Can the course of the illness be altered?. Biological Psychiatry 1995; 38: 1–3
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy RD. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophrenia Research 2000a; 42: 7–17
   PubMed Web of Science ®Google Scholar
• Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophrenia Bulletin 2004; 30: 923–934
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, McElhinny LG, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. Journal of Psychiatric Research 1998a; 32: 385–391
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, van Kammen DP. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Research 2000b; 97: 137–151
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Research 1998b; 80: 29–39
   PubMed Web of Science ®Google Scholar
• Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287–310
   PubMed Web of Science ®Google Scholar
• Yao JK, van Kammen DP, Welker JA. Red cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994; 13: 217–226
   PubMedGoogle Scholar
• Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: Association with positive symptoms. Psychiatry Research 2003; 117: 85–88
   PubMed Web of Science ®Google Scholar